Zacks: Brokerages Anticipate Voyager Therapeutics, Inc. (VYGR) Will Announce Earnings of -$0.72 Per Share
Brokerages expect that Voyager Therapeutics, Inc. (NASDAQ:VYGR) will announce earnings per share (EPS) of ($0.72) for the current quarter, according to Zacks. Two analysts have made estimates for Voyager Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.82) and the highest estimate coming in at ($0.48). Voyager Therapeutics posted earnings of ($0.35) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 105.7%. The firm is scheduled to issue its next earnings report on Thursday, November 9th.
According to Zacks, analysts expect that Voyager Therapeutics will report full year earnings of ($2.87) per share for the current financial year, with EPS estimates ranging from ($3.09) to ($2.33). For the next year, analysts expect that the company will report earnings of ($2.73) per share, with EPS estimates ranging from ($3.47) to ($1.99). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. The business had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $3.27 million.
VYGR has been the subject of several recent analyst reports. Stifel Nicolaus restated a “buy” rating and set a $33.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, June 27th. Zacks Investment Research downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. BidaskClub raised shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 13th. ValuEngine cut shares of Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $27.86.
WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/23/zacks-brokerages-anticipate-voyager-therapeutics-inc-vygr-will-announce-earnings-of-0-72-per-share.html.
In other news, insider Bernard Ravina sold 16,470 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.87, for a total transaction of $211,968.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 32,940 shares of company stock worth $490,092. Corporate insiders own 8.00% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Voyager Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock valued at $3,860,000 after buying an additional 13,194 shares during the last quarter. DAFNA Capital Management LLC raised its holdings in shares of Voyager Therapeutics by 187.2% during the second quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock valued at $1,835,000 after buying an additional 133,488 shares during the last quarter. State Street Corp raised its holdings in shares of Voyager Therapeutics by 11.8% during the second quarter. State Street Corp now owns 184,526 shares of the company’s stock valued at $1,653,000 after buying an additional 19,471 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Voyager Therapeutics by 26.8% during the second quarter. Northern Trust Corp now owns 133,571 shares of the company’s stock valued at $1,197,000 after buying an additional 28,222 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Voyager Therapeutics by 17.4% during the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock valued at $1,739,000 after buying an additional 19,450 shares during the last quarter. 40.70% of the stock is currently owned by institutional investors.
Voyager Therapeutics (VYGR) traded down 2.03% during mid-day trading on Monday, hitting $22.63. The stock had a trading volume of 198,107 shares. The firm’s market cap is $608.81 million. Voyager Therapeutics has a 12-month low of $8.10 and a 12-month high of $25.99. The company has a 50-day moving average of $18.58 and a 200-day moving average of $11.86.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.